DE Burlo Group Inc. Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

DE Burlo Group Inc. trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,290 shares of the biopharmaceutical company’s stock after selling 7,400 shares during the quarter. DE Burlo Group Inc.’s holdings in Gilead Sciences were worth $1,124,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Ballentine Partners LLC grew its holdings in Gilead Sciences by 4.9% during the first quarter. Ballentine Partners LLC now owns 4,973 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 234 shares during the last quarter. Hudson Capital Management LLC grew its holdings in Gilead Sciences by 11.2% during the first quarter. Hudson Capital Management LLC now owns 21,118 shares of the biopharmaceutical company’s stock valued at $1,373,000 after purchasing an additional 2,125 shares during the last quarter. Long Road Investment Counsel LLC grew its holdings in Gilead Sciences by 4.1% during the first quarter. Long Road Investment Counsel LLC now owns 25,600 shares of the biopharmaceutical company’s stock valued at $1,664,000 after purchasing an additional 1,000 shares during the last quarter. Oak Associates Ltd. OH grew its holdings in Gilead Sciences by 14.5% during the first quarter. Oak Associates Ltd. OH now owns 338,901 shares of the biopharmaceutical company’s stock valued at $22,032,000 after purchasing an additional 43,032 shares during the last quarter. Finally, Wesbanco Bank Inc. grew its holdings in Gilead Sciences by 3.3% during the first quarter. Wesbanco Bank Inc. now owns 28,991 shares of the biopharmaceutical company’s stock valued at $1,884,000 after purchasing an additional 929 shares during the last quarter. 78.68% of the stock is owned by institutional investors and hedge funds.

In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $62.61, for a total value of $169,047.00. Following the sale, the director now owns 57,560 shares in the company, valued at approximately $3,603,831.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 5,816 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the sale, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. Insiders sold a total of 29,018 shares of company stock worth $1,914,428 in the last 90 days. Company insiders own 0.20% of the company’s stock.

Several equities research analysts have recently issued reports on GILD shares. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, May 2nd. Credit Suisse Group started coverage on shares of Gilead Sciences in a research note on Monday, May 20th. They issued a “neutral” rating and a $70.00 price objective on the stock. JPMorgan Chase & Co. restated a “buy” rating and issued a $87.00 price objective on shares of Gilead Sciences in a research note on Tuesday, May 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, May 6th. Finally, BMO Capital Markets assumed coverage on Gilead Sciences in a research report on Thursday, March 14th. They issued an “outperform” rating and a $78.00 target price for the company. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $79.54.

GILD stock traded up $0.48 during midday trading on Friday, reaching $67.56. The stock had a trading volume of 6,782,265 shares, compared to its average volume of 7,131,704. The company has a market capitalization of $85.01 billion, a price-to-earnings ratio of 10.99, a price-to-earnings-growth ratio of 3.11 and a beta of 1.10. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61. The business’s fifty day moving average price is $66.14. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the previous year, the company earned $1.48 EPS. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. Equities analysts anticipate that Gilead Sciences, Inc. will post 6.6 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.73%. The ex-dividend date of this dividend was Thursday, June 13th. Gilead Sciences’s payout ratio is 40.98%.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: Compound Interest and Why It Matters When Investing

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.